# Acura Pharmaceuticals, Inc. (ACUR)

> Source: Nexqual · https://nexqual.com/ACUR · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Acura Pharmaceuticals, Inc. (ACUR), nexqual.com/ACUR" · informational, not investment advice.

**Price:** USD 0 (+0.00% on the day) · last close of Oct 22, 2026; US market closed, not a live price. Prev close 0 · day 0–0 · 52w 0–0.01 · market cap $7K · PNK

## Key facts
- Total return with dividends: 1Y -80.0% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -80.0% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -80.2% | -82.2% |
| Volatility (annualized) | 637.0% | 558.2% |
| Max drawdown | -99.0% (Mar 2026→Apr 2026) | -100.0% (Nov 2021→Dec 2023) |

## Peers (Drug Manufacturers - Specialty & Generic)
SUPN (Supernus Pharmaceuticals, Inc.) USD 40.7 -3.26% · BHC (Bausch Health Companies Inc.) USD 6.44 -0.77% · HCM (HUTCHMED (China) Limited) USD 14.36 +0.56% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.2 -4.80% · RGC (Regencell Bioscience Holdings L) USD 7.67 -21.81% · LQDA (Liquidia Corporation) USD 42.65 +7.46%

## More
Full page: https://nexqual.com/ACUR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends 2017-09-30) | — | — | — | $0 | — |
| Current fiscal year (ends 2017-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |